共查询到17条相似文献,搜索用时 296 毫秒
1.
2.
3.
4.
5.
6.
[目的]研究新型血清标志物Monototal在非小细胞肺癌诊断中的临床应用价值。[方法]选取197例非小细胞肺癌患者、35例肺部良性疾病患者和120例健康体检血清标本,检测CA125、CEA、CYFRA21-1、SCC和Monototal水平。采用SPSS 19.0进行统计分析,比较不同血清肿瘤标志物诊断非小细胞肺癌的敏感度和特异性。[结果]非小细胞肺癌组血清Monototal中位浓度是53.19U/L,显著性高于肺部良性组(41.60U/L)和健康体检组(5.55U/L)(P均<0.01)。血清Monototal诊断非小细胞肺癌的敏感度(30.46%)和特异性(91.43%)与Cyfra21-l(38.07%,94.29%)较为接近。不同临床分期中,Monototal诊断Ⅰ期肺癌的敏感度最高,为19.05%,Cyfra21-1则为17.86%。Cyfra21-1诊断Ⅱ、Ⅲ、Ⅳ期肺癌的敏感度最高,分别为46.51%、61.90%和75.00%;而Monototal则分别为30.23%、50.00%和41.67%。[结论 ]Monototal是一种较好的非小细胞肺癌肿瘤标志物,对非小细胞肺癌的诊断效能接近Cyfra21-1,对早期非小细胞肺癌辅助诊断可能有更好的诊断价值。 相似文献
7.
8.
9.
摘 要:[目的] 探讨血浆p16基因甲基化联合p53抗体水平的检测对非小细胞肺癌早期诊断价值和临床意义。[方法] 选择98例非小细胞肺癌患者为实验组,以60名健康者作对照,分别采用巢式甲基化特异性聚合酶链反应法检测其血浆p16基因甲基化,用酶联免疫吸附法(ELISA)检测其血浆p53抗体。[结果] 非小细胞肺癌组的p16基因甲基化率(χ2=45.709,P<0.001)、p53抗体表达量(Z=-5.786,P<0.001)、p53抗体定性阳性率(χ2=41.638,P<0.001)均高于健康对照组。p16基因甲基化和p53抗体表达及定性检测对非小细胞肺癌预测诊断的敏感度分别为70.41%和58.16%,特异性分别为85.00%和93.33%,正确指数为0.554和0.515。p16基因甲基化和p53抗体定量联合检测结果对非小细胞肺癌诊断的敏感度为82.56%,特异性为78.33%,正确指数为0.610。p16基因甲基化与p53抗体检测具有相关性(r=0.215,P=0.029)。[结论] 非小细胞肺癌患者血浆中p16基因甲基化与p53抗体可以作为非小细胞肺癌预测诊断的肿瘤标志物,联合检测的预测敏感度高于单独检测。 相似文献
10.
目的 探讨血清5种肿瘤标志物联合检测在肺癌诊断中的价值。方法 采用电化学发光免疫法检测168例肺癌患者、46例肺良性疾病患者及健康对照组癌胚抗原(CEA)、糖类抗原125 (CA125)、糖类抗原15-3 (CA15-3)、细胞角蛋白19 片段(CYFRA21-1)和神经元特异性烯醇化酶(NSE)水平,并计算上述指标联合检测在肺癌诊断中的敏感度、特异度、准确度和约登指数(YI)。结果 肺癌组5种肿瘤标志物水平均明显高于肺良性疾病组和健康对照组(P<0.01)。这5种血清肿瘤标志物在肺癌的不同病理类型、临床分期之间均有不同程度的差异。单项检测各种肿瘤标志物诊断肺癌的敏感度、准确度和YI)以CYFRA21-1最高,分别为58.9 %、65.9 %和0.37 %。联合检测较单项检测敏感性、准确性和YI明显提高,5项联合检测敏感度95.8 %、特异度79.2 %、准确度87.9 %、YI为0.75。结论 单项检测对肺癌的诊断价值有限,5种血清肿瘤标志物联合检测可提高肺癌的敏感度和准确度。 相似文献
11.
目的:评价一组肿瘤相关自身抗体(tumor-associated autoantibodies,T-AABs),包括p53、PGP9.5、SOX2、GAGE7、GBU4-5、MAGE-A1和CAGE,在恶性肺结节中的诊断价值,评估7-AABs与肿瘤标志物血清癌胚抗原(carcinoembryonic antigen,CEA)、神经元特异性烯醇化酶(neuron specific enolase,NSE)、细胞角蛋白19片段21-1(cytokeratin 19 fragment 21-1,CYFRA 21-1)水平和Mayo模型联合诊断恶性肺结节的价值,并分析7-AABs与CT影像学征象的相关性。方法:选取东南大学附属中大医院2016年12月至2019年02月经手术取得的208例肺结节患者病理结果。采用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELI-SA)检测血浆AABs水平,同时对比并结合CEA、NSE、CYFRA 21-1和Mayo模型,分析其在恶性肺结节诊断中的价值。采用χ^2检验或t检验分析AABs阳性表达与CT征象的相关性。结果:7-AABs在恶性肺结节中的敏感性、特异性和阳性预测值(positive predictive value,PPV)分别为54.7%、87.9%和92.1%。7-AABs与肿瘤标志物联合检测的敏感性高达70.0%。7-AABs与Mayo模型联合诊断恶性肺结节的曲线下面积(AUC)为0.699。7-AABs阳性表达与短毛刺征、空泡征具有相关性(均P<0.05)。结论:7-AABs水平对良恶性肺结节的鉴别有一定价值,联合肿瘤标志物、Mayo模型检测可提高恶性肺结节的诊断效能,7-AABs阳性表达与短毛刺征、空泡征相关,可能有助于良恶性肺结节的鉴别。 相似文献
12.
13.
Seregni E Foa P Bogni A Botti C Cataldo I Sala M Mezzetti M Gasparini M Santambrogio L Legnani D Bombardieri E 《Oncology reports》1996,3(1):95-101
This study compared the diagnostic efficacy of serum CK19 determination (Cyfra 21-1) with other tumour markers, such as CEA, SCC, NSE, TPA, in patients with resected non-small lung cancer. Tumour marker levels were tested in 90 patients with benign lung disease and at diagnosis in 72 patients with proven NSCLC, 39 squamous cell carcinoma and 33 adenocarcinoma. At presentation baseline levels of all tumor markers were significantly higher (p<0.05) in lung cancer patients than in control subjects, except for NSE. A significant increase (p<0.05) in serum concentrations was observed from stage I to stage IIIb only for Cyfra 21-1 (stage I/II, median=2.7 ng/ml; stage IIIb, median=6.3 ng/ml) and TPA (stage I/II, median=89.8 IU/ml; stage IIIb, median=170.7 IU/ml). Receiver operating characteristic (ROC) analysis was performed to evaluate the best threshold values and the global accuracy of each marker. The highest global sensitivity for NSCLC was reached by TPA (70.8%), whereas that of Cyfra 21-1 was 50%. According to tumour histology, significant difference (p<0.05) in serum levels were found only for CEA (adenocarcinomas, median=5.6 ng/ml; squamous cell carcinoma, median=3.2 ng/ml) and SCC (adenocarcinomas, median=1.0 ng/ml; squamous cell carcinoma, median=1.5 ng/ml). As regards squamous cell carcinoma histotype, the highest sensitivity was obtained by TPA (74.4% at a specificity of 62.2%) and for adenocarcinomas by CEA (78.8% at a specificity of 85.6%). Tumour marker levels were also determined during the follow-up of 10 patients. The best sensitivity in detecting relapses was shown by CEA (90%), followed by TPA (70%), SCC (50%), Cyfra 21-1 (40%) and NSE (10%), even though the CEA test displayed a high percentage of false positive results (98.1%) in patients with no evidence of disease (NED). 相似文献
14.
15.
非小细胞肺癌血清VEGF与CA125 CEA Cyfra21-1 的相关性及临床意义* 总被引:4,自引:1,他引:3
目的:探讨化疗前血清血管内皮生长因子(VEGF)检测在非小细胞肺癌(NSCLC )中的临床应用价值,同时测定血清中CA125、CEA 、Cyfra21-1 的滴度及其相关性。方法:采用抗人VEGF单克隆抗体、夹心ELISA 法测定78例NSCLC 患者血清VEGF浓度。同时利用放射免疫法检测血清中CEA 、CA125、Cyfra21-1 的浓度。结果:NSCLC 有远处转移组血清VEGF、CA125、CEA 浓度显著高于无远处转移组(P<0.05);有淋巴结转移组血清VEGF显著高于无淋巴结转移组(P<0.05)。 血清VEGF和CA125、CEA 在Ⅲ+ Ⅳ期NSCLC 的表达显著高于I+II 期NSCLC(P<0.05)。 血清CEA 在腺癌中显著增高(P<0.05)。 血清VEGF、CA125 阴性组的化疗有效率(35.3% 、35.7%)显著高于阳性组(7.7% 、15.8%)(P=0.004,0.006)。 化疗前血清CEA 阴性者的中位总生存时间(mOS )较阳性者明显延长(分别为36个月,20个月;P=0.04);而血清VEGF、Cyfra21-1、CA125 浓度对mOS 无明显影响(P 值分别为0.07,0.099,0.19)。 血清CEA 、VEGF、Cyfra21-1、CA125 表达对中位无瘤生存期(mTTP)均无明显影响(P 值分别为0.119,0.280,0.146,0.230)。 NSCLC 患者血清VEGF 与CEA 表达存在显著正相关(P<0.05),其他肿瘤标志物之间无显著相关性(P>0.05)。 结论:综合检测NSCLC 患者化疗前血清肿瘤标志物可能有利于协助诊断、预测转移、评价化疗疗效及判断预后。 相似文献
16.
17.
Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer 总被引:5,自引:0,他引:5
Reinmuth N Brandt B Semik M Kunze WP Achatzy R Scheld HH Broermann P Berdel WE Macha HN Thomas M 《Lung cancer (Amsterdam, Netherlands)》2002,36(3):265-270
PURPOSE: The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection. METHODS: Sixty-seven patients with histologically proven NSCLC and complete resection of stage I-IIIA disease were included. The serum levels of all markers were measured using commercially available immunoassays. RESULTS: With a median follow-up of 86 months for surviving patients, those with initial Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (P=0.014). The remaining serum tumor markers showed no prognostic impact. In a Cox regression model, Cyfra21-1 proved to be an independent prognostic factor for both overall survival and disease-free interval. In addition, Cyfra21-1 sustained as an independent prognostic factor in completely resected stage I/II disease. CONCLUSIONS: With a cut-off value of 3.57 ng/ml, Cyfra 21-1 was an independent prognostic factor for survival in NSCLC-patients with complete resection. Further evaluation is needed, particularly in stage I/II disease. When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC. 相似文献